Develops precision T cell therapies for cancer, targeting clonal neoantigens to enhance treatment efficacy.
Achilles Therapeutics Plc operates as a clinical-stage biopharmaceutical company specializing in immuno-oncology, focusing on the development of precision T cell therapies for the treatment of various solid tumors. Founded in 2016 and headquartered in London, United Kingdom, the company has positioned itself at the forefront of advancing innovative treatments that harness the body's immune system to target cancer cells.
At the heart of Achilles Therapeutics' pipeline are its lead product candidates, CHIRON and THETIS, both undergoing Phase I/IIa clinical trials. CHIRON is being evaluated for its potential in treating advanced non-small cell lung cancer, while THETIS is aimed at metastatic or recurrent melanoma. The company is also actively developing therapies for additional cancer types including head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer, underscoring its commitment to addressing diverse oncological challenges.
Formerly known as Achilles TX Limited, the company rebranded to Achilles Therapeutics Plc in February 2021 to reflect its expanded focus and growth within the immuno-oncology field. With a robust research and development strategy coupled with strategic partnerships, Achilles Therapeutics continues to push the boundaries of cancer treatment innovation, aiming to deliver meaningful therapeutic options to patients worldw ide.